FDA Approval Insights: Tepotinib in METex14-Altered Metastatic NSCLC

Season 4 Episode 36  ·  Mar 01, 2021, 08:01 PM

Headliner
Share
Subscribe

In our exclusive interview, Paul K. Paik, MD, provides perspective on the FDA approval of tepotinib in MET exon 14-altered metastatic NSCLC.

Share
Subscribe
Next
Heymach Homes in On Emerging Agents in EGFR Exon 20–Mutant NSCLC
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air